Cost-utility analysis of teriflunomide in naïve vs. previously treated patients with relapsing–remitting multiple sclerosis in Italy
Carlo Lazzaro(Ospedale Annunziata di Cosenza), Damiano Paolicelli(University of Bari Aldo Moro), Mauro Zaffaroni(Associazione Italiana Sclerosi Multipla), Roberto Bergamaschi(Fondazione Istituto Neurologico Nazionale Casimiro Mondino), Rocco Totaro(San Salvatore Hospital)
Cited by 6
Related Papers
Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN)
|The Lancet|2002|552
Multiple sclerosis in childhood: clinical features of 149 cases
|Multiple Sclerosis Journal|1997|309
Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study
|Multiple Sclerosis Journal|2015|298
Clinical characteristics, course and prognosis of relapsing Devic?s Neuromyelitis Optica
|Journal of Neurology|2004|268
Assessment of Normal-Appearing White and Gray Matter in Patients With Primary Progressive Multiple Sclerosis
|Archives of Neurology|2002|223